{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T17:05:12Z","timestamp":1779728712511,"version":"3.53.1"},"reference-count":34,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales d'Endocrinologie"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.ando.2026.102522","type":"journal-article","created":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T16:17:27Z","timestamp":1774023447000},"page":"102522","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["How has genetics changed the diagnosis and care of multiple endocrine neoplasia type 2? The merits and pitfalls of a genetic-based diagnostic and therapeutic approach"],"prefix":"10.1016","volume":"87","author":[{"given":"Frederic","family":"Castinetti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Sahakian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Romanet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ando.2026.102522_bib0175","doi-asserted-by":"crossref","first-page":"T189","DOI":"10.1530\/ERC-18-0141","article-title":"65 years of the double helix: exploiting insights on the RET receptor for personalized cancer medicine","volume":"25","author":"Mulligan","year":"2018","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.ando.2026.102522_bib0180","doi-asserted-by":"crossref","DOI":"10.1530\/ERC-24-0226","article-title":"RET@Thirty: the story behind identification of RET mutation as the cause of MEN2 and what it meant to clinical practice","volume":"32","author":"Ponder","year":"2025","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.ando.2026.102522_bib0185","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ando.2023.11.005","article-title":"Updates on the genetics of multiple endocrine neoplasia","volume":"85","author":"Sahakian","year":"2024","journal-title":"Ann Endocrinol (Paris)"},{"key":"10.1016\/j.ando.2026.102522_bib0190","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/cen.14395","article-title":"Diagnostic RET genetic testing in 1,058 index patients: a UK centre perspective","volume":"95","author":"Fussey","year":"2021","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.ando.2026.102522_bib0195","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1089\/thy.2014.0335","article-title":"Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma","volume":"25","author":"Wells","year":"2015","journal-title":"Thyroid"},{"key":"10.1016\/j.ando.2026.102522_bib0200","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1530\/EC-18-0506","article-title":"Genotype and phenotype landscape of MEN2 in 554 medullary thyroid cancer patients: the BrasMEN study","volume":"8","author":"Maciel","year":"2019","journal-title":"Endocr Connect"},{"key":"10.1016\/j.ando.2026.102522_bib0205","article-title":"Redefining the prevalence of different clinical variants in MEN2A and their correlation with RET germline mutations: a single-center series and experience","volume":"33","author":"Romei","year":"2026","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.ando.2026.102522_bib0210","doi-asserted-by":"crossref","first-page":"4264","DOI":"10.1210\/jc.2019-00516","article-title":"Long-term outcomes and aggressiveness of hereditary medullary thyroid carcinoma: 40 years of experience at one center","volume":"104","author":"Raue","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2026.102522_bib0215","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/CCO.0000000000001009","article-title":"Multiple endocrine neoplasia type 2: towards a risk-based approach integrating molecular and biomarker results","volume":"36","author":"Machens","year":"2024","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.ando.2026.102522_bib0220","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1038\/s41431-018-0224-1","article-title":"Guidelines for reporting secondary findings of genome sequencing in cancer genes: the SFMPP recommendations","volume":"26","author":"Pujol","year":"2018","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.ando.2026.102522_bib0225","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1038\/s41436-021-01172-3","article-title":"ACMG SF v3.0 list for reporting of secondary findings in clinical exome and genome sequencing: a policy statement of the American College of Medical Genetics and Genomics (ACMG)","volume":"23","author":"Miller","year":"2021","journal-title":"Genet Med"},{"key":"10.1016\/j.ando.2026.102522_bib0230","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S2213-8587(18)30336-X","article-title":"Natural history, treatment, and long-term follow up of patients with multiple endocrine neoplasia type 2B: an international, multicentre, retrospective study","volume":"7","author":"Castinetti","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ando.2026.102522_bib0235","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.ejso.2018.09.002","article-title":"Prophylactic thyroidectomy in multiple endocrine neoplasia 2 (MEN2) patients with the C634Y mutation: A long-term follow-up in a large single-center cohort","volume":"45","author":"Febrero","year":"2019","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.ando.2026.102522_bib0240","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1515\/jpem-2018-0444","article-title":"Present status of prophylactic thyroidectomy in pediatric multiple endocrine neoplasia 2: a nationwide survey in Japan 1997\u20132017","volume":"32","author":"Matsushita","year":"2019","journal-title":"J Pediatr Endocrinol Metab"},{"key":"10.1016\/j.ando.2026.102522_bib0245","doi-asserted-by":"crossref","DOI":"10.1530\/ERC-24-0251","article-title":"MEN2: surgical precision in the era of precision medicine","volume":"32","author":"Kurzawinski","year":"2025","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.ando.2026.102522_bib0250","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1002\/bjs.10856","article-title":"Prophylactic thyroidectomy in children with multiple endocrine neoplasia type 2","volume":"105","author":"Prete","year":"2018","journal-title":"Br J Surg"},{"key":"10.1016\/j.ando.2026.102522_bib0255","doi-asserted-by":"crossref","first-page":"e1108","DOI":"10.1097\/MD.0000000000001108","article-title":"Postoperative complications after prophylactic thyroidectomy for very young patients with multiple endocrine neoplasia type 2: retrospective cohort analysis","volume":"94","author":"Kluijfhout","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.ando.2026.102522_bib0260","doi-asserted-by":"crossref","first-page":"E1813","DOI":"10.1210\/jc.2013-1653","article-title":"The characterization of pheochromocytoma and its impact on overall survival in multiple endocrine neoplasia type 2","volume":"98","author":"Thosani","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2026.102522_bib0265","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1007\/s12020-020-02332-2","article-title":"MEN2-related pheochromocytoma: current state of knowledge, specific characteristics in MEN2B, and perspectives","volume":"69","author":"Amodru","year":"2020","journal-title":"Endocrine"},{"key":"10.1016\/j.ando.2026.102522_bib0270","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/cen.13386","article-title":"Phaeochromocytoma in multiple endocrine neoplasia type 2: RET codon-specific penetrance and changes in management during the last four decades","volume":"87","author":"Mucha","year":"2017","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.ando.2026.102522_bib0275","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/S1470-2045(14)70154-8","article-title":"Outcomes of adrenal-sparing surgery or total adrenalectomy in phaeochromocytoma associated with multiple endocrine neoplasia type 2: an international retrospective population-based study","volume":"15","author":"Castinetti","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ando.2026.102522_bib0280","doi-asserted-by":"crossref","first-page":"R9","DOI":"10.1530\/EJE-15-0549","article-title":"Management of endocrine disease: outcome of adrenal sparing surgery in heritable pheochromocytoma","volume":"174","author":"Castinetti","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2026.102522_bib0285","doi-asserted-by":"crossref","first-page":"T15","DOI":"10.1530\/ERC-17-0266","article-title":"Looking beyond the thyroid: advances in the understanding of pheochromocytoma and hyperparathyroidism phenotypes in MEN2 and of non-MEN2 familial forms","volume":"25","author":"Guerin","year":"2018","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.ando.2026.102522_bib0290","doi-asserted-by":"crossref","DOI":"10.3390\/diseases13040098","article-title":"An analysis of primary hyperparathyroidism in individuals diagnosed with multiple endocrine neoplasia type 2","volume":"13","author":"Gheorghe","year":"2025","journal-title":"Diseases"},{"key":"10.1016\/j.ando.2026.102522_bib0295","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1097\/SLA.0000000000001464","article-title":"Management of the parathyroid glands during preventive thyroidectomy in patients with multiple endocrine neoplasia type 2","volume":"262","author":"Moley","year":"2015","journal-title":"Ann Surg"},{"key":"10.1016\/j.ando.2026.102522_bib0300","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/978-3-031-80396-3_9","article-title":"Primary hyperparathyroidism in MEN2 syndromes","volume":"223","author":"Saltiki","year":"2025","journal-title":"Recent Results Cancer Res"},{"key":"10.1016\/j.ando.2026.102522_bib0305","doi-asserted-by":"crossref","first-page":"T1","DOI":"10.1530\/ERC-17-0325","article-title":"Advances in the management of MEN2: from improved surgical and medical treatment to novel kinase inhibitors","volume":"25","author":"Wells","year":"2018","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.ando.2026.102522_bib0310","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1210\/clinem\/dgaf089","article-title":"Approach to the patient: hereditary medullary thyroid carcinoma","volume":"110","author":"Shariq","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2026.102522_bib0315","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1177\/10507256251367352","article-title":"Patient-reported tolerability of selpercatinib compared to cabozantinib\/vandetanib: a secondary analysis of the LIBRETTO-531 randomized-controlled trial in RET-mutant medullary thyroid cancer","volume":"35","author":"Elisei","year":"2025","journal-title":"Thyroid"},{"key":"10.1016\/j.ando.2026.102522_bib0320","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1056\/NEJMoa2309719","article-title":"Phase 3 trial of selpercatinib in advanced RET-mutant medullary thyroid cancer","volume":"389","author":"Hadoux","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ando.2026.102522_bib0325","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1200\/JCO.23.02503","article-title":"Durability of response with selpercatinib in patients with RET-activated thyroid cancer: long-term safety and efficacy from LIBRETTO-001","volume":"42","author":"Wirth","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ando.2026.102522_bib0330","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1089\/thy.2024.0495","article-title":"Efficacy and safety of selective RET inhibitors in patients with advanced hereditary medullary thyroid carcinoma","volume":"35","author":"Hamidi","year":"2025","journal-title":"Thyroid"},{"key":"10.1016\/j.ando.2026.102522_bib0335","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ando.2024.02.001","article-title":"RET kinase inhibitors for the treatment of RET-altered thyroid cancers: current knowledge and future directions","volume":"85","author":"Hamidi","year":"2024","journal-title":"Ann Endocrinol (Paris)"},{"key":"10.1016\/j.ando.2026.102522_bib0340","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1089\/thy.2016.0399","article-title":"Nationwide French Study of RET variants detected from 2003 to 2013 Suggests a possible influence of polymorphisms as modifiers","volume":"27","author":"Lebeault","year":"2017","journal-title":"Thyroid"}],"container-title":["Annales d'Endocrinologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003426626000430?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003426626000430?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T16:26:09Z","timestamp":1779726369000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003426626000430"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S0003426626000430"],"URL":"https:\/\/doi.org\/10.1016\/j.ando.2026.102522","relation":{},"ISSN":["0003-4266"],"issn-type":[{"value":"0003-4266","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"How has genetics changed the diagnosis and care of multiple endocrine neoplasia type 2? The merits and pitfalls of a genetic-based diagnostic and therapeutic approach","name":"articletitle","label":"Article Title"},{"value":"Annales d'Endocrinologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ando.2026.102522","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"102522"}}